Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicenter, double-blind, randomized, placebo-controlled trial to evaluate the efficacy and safety of apraglutide in adult subjects with short bowel syndrome and intestinal failure (SBS-IF)

Next Previous
Trial Profile

A multicenter, double-blind, randomized, placebo-controlled trial to evaluate the efficacy and safety of apraglutide in adult subjects with short bowel syndrome and intestinal failure (SBS-IF)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 20 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Apraglutide (Primary)
  • Indications Intestinal disorders; Intestinal failure; Short bowel syndrome
  • Focus Registrational; Therapeutic Use
  • Acronyms STARS
  • Sponsors Ironwood Pharmaceuticals; VectivBio

Most Recent Events

  • 14 Apr 2025 According to an Ironwood Pharmaceuticals media release, in preparation for the NDA submission, pharmacokinetic analysis from this study indicated that the exposure and dose delivered were lower than planned due to dose preparation and administration. Consistent with FDA discussions, Ironwood plans to continue the long-term extension trial and believes the data from the this trial will continue to be an integral part of an NDA submission package.
  • 28 Oct 2024 According to an Ironwood Pharmaceuticals media release, the company will present new findings at the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting and Postgraduate Course from subgroup analyses of the primary endpoint of the pivotal Phase III clinical trial.
  • 28 Oct 2024 Results presented in an Ironwood Pharmaceuticals Media Release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top